Metformin prescription is associated with reduced risk of surgical repair and rupture-related mortality in patients with abdominal aortic aneurysm

Golledge, Jonathan, Morris, Dylan R., Pinchbeck, Jenna, Rowbotham, Sophie, Jenkins, Jason, Bourke, Michael, Bourke, Bernard, Norman, Paul E., Jones, Rhonda, and Moxon, Joseph V. (2019) Metformin prescription is associated with reduced risk of surgical repair and rupture-related mortality in patients with abdominal aortic aneurysm. European Journal of Vascular and Endovascular Surgery, 57 (1). pp. 94-101.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website:


Objectives: Currently there is no drug therapy for abdominal aortic aneurysm (AAA) and most previous investigations have focused on imaging rather than clinical outcomes. The aim of this study was to assess whether AAA related clinical events were lower in patients prescribed metformin.

Methods: This was a prospective cohort observational study performed in three cities in Australia, which was designed to study risk factors for clinical events not simply to focus on metformin. Patients with an asymptomatic unrepaired AAA of any diameter ≥30 mm were recruited from hospital outpatient clinics and surveillance programs run at four centres. The main outcome was the requirement for AAA repair or AAA related mortality (AAA events). The association between metformin prescription and AAA events was assessed using Kaplan-Meier analysis and Cox proportional hazard analysis.

Results: Patients (1,080) with a mean (SD) initial AAA diameter of 46.1 (11.3) mm were followed for a mean (SD) of 2.5 (3.1) years until an AAA event (n ¼ 454), death (n ¼ 176), loss to follow up (n ¼ 128), or completion of current follow up (n ¼ 322). Patients with diabetes who were prescribed metformin (adjusted HR 0.63, 95% CI 0.44e0.93), but not patients with diabetes who were not prescribed metformin (adjusted HR 1.15, 95% CI 0.83e 1.59), had a lower incidence of AAA events compared with those without diabetes. Findings were similar in sensitivity analyses restricted to patients with an initial AAA diameter ≤ 50 mm and patients with a minimum follow up of six months before an AAA event.

Conclusions: These findings suggest that clinically important AAA events may be reduced in patients with diabetes who are prescribed metformin, but not those with diabetes receiving other treatments. A randomised controlled trial is needed to definitively test whether metformin reduces AAA related clinical events in patients with small AAAs who do not have diabetes.

Item ID: 57943
Item Type: Article (Research - C1)
ISSN: 1532-2165
Copyright Information: (c) 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.
Additional Information:

Full text available via publisher's website.

Funders: National Health and Medical Research Council of Australia (NHMRC), Queensland Government
Projects and Grants: NHMRC 1022757, NHMRC 1117061
Date Deposited: 21 Oct 2019 23:39
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3201 Cardiovascular medicine and haematology > 320101 Cardiology (incl. cardiovascular diseases) @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100%
Downloads: Total: 1
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page